Currency In USD
| Previous Close | 4.29 |
| Open | 4.3 |
| Day High | 4.3 |
| Day Low | 3.91 |
| 52-Week High | 5.17 |
| 52-Week Low | 1.69 |
| Volume | 1.42M |
| Average Volume | 3.14M |
| Market Cap | 339.18M |
| PE | -3.44 |
| EPS | -1.19 |
| Moving Average 50 Days | 3.72 |
| Moving Average 200 Days | 2.75 |
| Change | -0.2 |
C4 Therapeutics to Participate in Upcoming March Conferences
GlobeNewswire Inc.
Feb 23, 2026 12:10 PM GMT
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will p
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
GlobeNewswire Inc.
Feb 23, 2026 12:00 PM GMT
Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T)
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will p